Santhera Pharmaceuticals Holding (CH:SANN)
:SANN
Want to see CH:SANN full AI Analyst Report?
Top Page
Santhera Pharmaceuticals Holding
(SANN)
Select Model
Select Model
Rating:44Neutral
Price Target:
CHF17.00
▼(-3.52% Downside)
Action:Reiterated
Date:05/28/26
The score is held down primarily by weak financial quality—negative equity, higher debt, recurring losses, and ongoing cash burn—despite a strong 2025 revenue rebound. Technical indicators also point to weak near-term momentum, while valuation is difficult to assess due to negative earnings and no dividend data.
Positive Factors
Approved rare-disease product
Owning an approved, disease-specific therapy creates a durable commercial foundation: AGAMREE targets a small, high-need DMD population where reimbursement and pricing can be favorable. This focused product reduces commercial complexity and supports recurring product revenues and partner interest.
Negative Factors
Weakened balance sheet
Negative equity and a sharp increase in debt materially reduce financial flexibility and raise refinancing risk. With limited reserves, the company may face constrained ability to fund launches, invest in trials, or negotiate favourable partner terms absent new capital or asset sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Approved rare-disease product
Owning an approved, disease-specific therapy creates a durable commercial foundation: AGAMREE targets a small, high-need DMD population where reimbursement and pricing can be favorable. This focused product reduces commercial complexity and supports recurring product revenues and partner interest.
Read all positive factors
Santhera Pharmaceuticals Holding (SANN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF238.72M
Dividend YieldN/A
Average Volume (3M)55.85K
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth97.32%
EPS Growth-11.07%
CountryCH
Employees78
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.82
Shares Outstanding15,456,525
10 Day Avg. Volume57,231
30 Day Avg. Volume55,851
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)-13.88
Price to Sales (P/S)2.12
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF30.00Price Target Upside70.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.6
Revenue Forecast (FY)CHF96.35M
Santhera Pharmaceuticals Holding Business Overview & Revenue Model
Company Description
Santhera Pharmaceuticals Holding AG is a specialized biopharmaceutical firm dedicated to advancing and distributing therapeutic solutions for rare neurological and respiratory conditions characterized by significant patient need across the globe, ...
How the Company Makes Money
Santhera makes money primarily by commercializing its rare-disease medicines and by monetizing product rights through partnerships. The main revenue stream is product-related income from AGAMREE (vamorolone), generated from sales in territories wh...
Santhera Pharmaceuticals Holding Earnings Call Summary
Earnings Call Date:Sep 23, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Sep 21, 2026
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.Positive Updates
Strong AGAMREE Adoption in Key Markets
AGAMREE has achieved approximately 40% market share of steroid using DMD patients in Germany and Austria, with Austria exceeding 50% market share.
Negative Updates
Operating Loss
Santhera reported an operating loss of CHF 35.4 million for the first half of the year.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong AGAMREE Adoption in Key Markets
AGAMREE has achieved approximately 40% market share of steroid using DMD patients in Germany and Austria, with Austria exceeding 50% market share.
Read all positive updates
Company Guidance
During the Santhera Pharmaceuticals half-year results call for the fiscal year 2025, Catherine Isted, the CFO, provided key financial guidance and metrics. The company announced new financing of CHF 20 million, extending their runway to cash flow breakeven by mid-2026. Santhera's cash balance was CHF 18.4 million as of June 30, 2025. The company's global sales reached over $100 million, and they expect full-year revenues to exceed CHF 65-70 million. Sales from their U.S. partner, Catalyst, were USD 49.4 million in H1 2025, with a full-year forecast of $100-110 million. This could trigger a $12.5 million milestone payment. Additionally, they anticipate strong growth in China following Sperogenix's commercial rollout, with over 250 patients already on AGAMREE. Santhera is expanding its market presence with recent launches in the U.K. and other European countries, aiming for a market size exceeding $600 million, including potential revenues from Europe, North America, and China as well as distribution agreements in other regions.Santhera Pharmaceuticals Holding Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 77.19M | 39.12M | 103.41M | 7.47M | -1.59M |
| Gross Profit | 14.47M | 22.96M | 100.18M | 3.88M | -5.36M |
| EBITDA | -32.13M | -15.89M | 79.17M | -46.78M | -34.57M |
| Net Income | -49.24M | -41.97M | 54.78M | -71.08M | -55.53M |
Balance Sheet | |||||
| Total Assets | 148.09M | 152.49M | 109.63M | 63.73M | 91.12M |
| Cash, Cash Equivalents and Short-Term Investments | 22.44M | 40.92M | 30.37M | 1.35M | 21.21M |
| Total Debt | 97.77M | 41.17M | 23.03M | 44.44M | 42.98M |
| Total Liabilities | 159.90M | 124.79M | 49.69M | 107.41M | 89.79M |
| Stockholders Equity | -11.82M | 27.70M | 59.94M | -43.69M | 1.33M |
Cash Flow | |||||
| Free Cash Flow | -34.81M | -35.68M | 23.53M | -33.80M | -37.37M |
| Operating Cash Flow | -34.76M | -35.53M | 47.27M | -29.84M | -37.36M |
| Investing Cash Flow | -122.00K | -61.00K | -18.04M | -3.93M | 69.00K |
| Financing Cash Flow | 16.38M | 46.08M | -171.00K | 13.99M | 46.02M |
Santhera Pharmaceuticals Holding Technical Analysis
Positive
17.62
Price Trends
16.67
Negative
15.90
Positive
13.93
Positive
Market Momentum
-0.25
Negative
48.81
Neutral
48.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SANN, the sentiment is Positive. The current price of 17.62 is above the 20-day moving average (MA) of 15.88, above the 50-day MA of 16.67, and above the 200-day MA of 13.93, indicating a neutral trend. The MACD of -0.25 indicates Negative momentum. The RSI at 48.81 is Neutral, neither overbought nor oversold. The STOCH value of 48.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:SANN.
Santhera Pharmaceuticals Holding Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF622.97M | 19.16 | ― | ― | 11.43% | -48.80% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | CHF1.48B | -6.69 | ― | ― | 35.80% | 24.01% | |
50 Neutral | CHF254.25M | -19.94 | ― | ― | -63.05% | -187.61% | |
44 Neutral | CHF238.72M | -4.39 | -301.13% | ― | 97.32% | -11.07% | |
43 Neutral | CHF125.97M | -2.01 | -51.05% | ― | -100.00% | 9.23% |
* Healthcare Sector Average
CH:SANN
Santhera Pharmaceuticals Holding
15.94
4.14
35.08%
CH:MOLN
Molecular Partners AG
3.09
0.19
6.74%
CH:BSLN
Basilea Pharmaceutica
51.30
2.45
5.02%
CH:IDIA
Idorsia Ltd
5.68
3.78
198.68%
CH:NWRN
Newron Pharmaceuticals SpA
12.20
5.09
71.59%
CH:XLS
Xlife Sciences Ltd.
25.20
5.55
28.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.